Citations

Clear

144 citation(s) found for "Hopkins, David".

Establishment of a brain tumor consortium of Africa: Advancing collaborative research and advocacy for brain tumors in Africa
Odukoya, Lateef A , Darko, Kwadwo , Zerd, Francis , Ghomsi, Nathalie , Kabare, Gloria , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Kitange, Gaspar J. , Akinjo, Andrea O , Badmos, Kabir, Idowu, Olufemi Emmanuel , Karekezi, Claire , Edrick, Elias, Katasi, Victoria Mwebe , Magambo, Margreth, Magoha, Michael, Ngaiza, Advera , Okemwa, Minda, Osei‐Tutu, Lawrence, Petershie, Bernard, Yevudza, W Elorm , Anunobi, C C , Tiamiyu, Liadi, Gankpé, Gbètoho Fortuné, Heronima, Kashaigili, Higgins, Dominique, Schroeder, Kristin, Totimeh, Teddy , Cheserem, Beverly , Gankpé, Fortuné Gbètoho , Schroeder, Kristin , Jenkins, RB , Karekezi, Claire , Brown, Desmond A., Huse, Jason T. , Balogun, James , Schroeder, Kristin , Zerd, Francis , Odukoya, Lateef A , Darko, Kwadwo , Idowu, Olufemi E , Kamson, David , Bankole, Olufemi , Ekhator, Chukwuyem , Brown, Desmond , LLEWELLYN, HENRY J. , Barrie, Umaru , Nyalundja, Arsène Daniel , Schroeder, Kristin, Etame, Arnold B. , Fonkem, Ekokobe

Mayo Clinic

Neuro-Oncology Advances | November 16, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae198 | PMID 39659834 Get It

Abstract Background Brain tumors represent a significant global health challenge, with rising incidence and mortality impacting individuals worldwide and contributing to cancer-related morbidity and mortality. In Africa, this burden is exacerbated by limited access to advanced diagnostics, treatment options, and multidisciplinary care, compounded by the absence of standardized cancer registration and tumor biobanking. The introduction of molecular diagnostics, as outlined in the 2021 World Health Organization central nervous system (CNS) tumor classification, adds complexity to brain tumor management, particularly in regions with scarce resources. Methods To address these issues, the Brain Tumor Consortium for Africa (BTCA) was established in 2023, bringing together experts to improve CNS tumor diagnosis, patient care, and research. The initial project, conducted via an electronic questionnaire, aimed to assess neuro-oncology capacity across Sub-Saharan Africa. Results The study revealed significant gaps, with a limited number of institutions incorporating molecular subtyping into their diagnostic algorithms. The consortium’s efforts focus on enhancing local data use, informing public policy, and promoting collaboration to advance neuro-oncology practices in Africa. By fostering a network enlisting the expertise of collaborators in the fields of neurosurgery, neurology, neuropathology, anatomic pathology, and medical and radiation oncology, the BTCA seeks to improve brain tumor management through better diagnostics, infrastructure, and policy advocacy. Future directions include expanding molecular diagnostic capabilities, standardizing brain tumor biobanking, enhancing data collection, and advocating for improved brain tumor care in national health agendas. Conclusions The BTCA represents a pioneering model of collaboration and innovation in addressing the unique challenges of brain tumor care in Africa.
Abstract 4145459: Lower Extremity Extracorporeal Distal Revascularization (LEEDR) as a Novel Approach to Limb Salvage with Prolonged Ischemia
Rodrigues, Diego V.S. , Price, Colin, Jacobs, Julia , Stonko, David P. , Stonko, David P , Treffalls, Rebecca N. , Price, Colin, Jacobs, Julia, DeMartino, Randall R. , Walker, Patrick, Morrison, Jonathan J.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4145459 Get It

Background: Acute limb ischemia (ALI) requires prompt revascularization to preserve the extremity and minimize the effects of systemic reperfusion. Once ALI is recognized, delays in revascularization are generally due to system issues (e.g., transfer) and there is a need for a method of temporary extremity perfusion to reduce warm ischemic time. Lower Extremity Extracorporeal Distal Revascularization (LEEDR) is a percutaneous technique that uses a pump and circuit to deliver oxygenated blood into a pedal artery. Hypothesis: Extracorporeal perfusion can improve survival from ALI. Aims: The aim of this study is to use a swine model of prolonged hindlimb ischemia to compare survival and functional outcomes of LEEDR versus control (warm ischemia). Methods: Anesthetized female Yorkshire swine (40-60kg) underwent hindlimb ischemia using endovascular balloon occlusion and were randomized to control (n=6) or LEEDR (n=6). Controls underwent 9 hours of ischemia. LEEDR animals underwent contralateral femoral and ipsilateral posterior tibial artery cannulation followed by 8 hours of extracorporeal perfusion into the ischemic limb. Subjects were revascularized by removing the endovascular balloons, restoring extremity blood flow, and undergoing a 4-hour critical care period before extubation and observation for 48 hours. Primary outcome was survival and secondary outcomes included functional extremity scores (Tarlov Gait Score), compartment pressures (mmHg) and biochemical markers of reperfusion. Results: Survival was higher in animals undergoing LEEDR (83% vs. 0%; p=0.001), with most control animals succumbing to acute lung injury. LEEDR animals had a higher functional gait score (5.9±0.3 vs. 2.5±0.7; p<0.001) and lower compartment pressure (8±2 vs. 28±4; p=0.002) compared to controls. Biochemically, the LEEDR group had lower potassium (4.5±0.3 vs. 5.3±0.4; p=0.001) and lactate (1.2±0.5 vs. 2.0±0.7; p<0.001) measurements compared to controls during reperfusion and recovery. Conclusion: LEEDR can effectively mitigate 8 hours of extremity ischemia in a swine model, reducing mortality from reperfusion, while improving functional gait score and eliminating compartment syndrome. This percutaneous approach to ALI opens a new field of extracorporeal limb salvage, which can temporize extremity perfusion improving outcomes in patients who have traditionally had limited options due to prolonged warm ischemia.
DISP-07. CURRENT NEURO-ONCOLOGY CAPACITY IN SUB-SAHARAN AFRICAN COUNTRIES: A QUESTIONNAIRE-BASED SURVEY
Ghomsi, Nathalie , Kabare, Gloria , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Kitange, Gaspar J. , Akinjo, Andrea O , Badmos, Kabir, Idowu, Olufemi, Karekazi, Claire, Darko, Kwadwo, Edrick, Elias, Katasi, Victoria Mwebe , Magambo, Margreth, Magoha, Michael, Ngaiza, Advera , Higgins, Dominique, Okenwa, Minda, Osei‐Tutu, Lawrence, Petershie, Bernard, Yevudza, W Elorm , Anunobi, C C , Tiamiyu, Liadi, Gankpé, Gbètoho Fortuné, Heronima, Kashaigili, Shroeder, Kristin, Teddy, Totimeh, Cheserem, Beverly , Gankpé, Fortuné Gbètoho , Odukoya, Lateef A , Kamson, David , Bankole, Olufemi , Darko, Kwadwo , Ekhator, Chukwuyem , Lachance, Daniel Honore , Brown, Desmond , Huse, Jason T. , LLEWELLYN, HENRY J. , Nyalundja, Arsène Daniel , Fonkem, Ekokobe , Balogun, James , Zerd, Francis

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii148-viii148

10.1093/neuonc/noae165.0581 Get It

Abstract Brain tumors constitute significant morbidity and mortality in sub-Saharan Africa (SSA). There is no previous large-scale effort focusing on brain tumor genetics in SSA. This project aims to map out the current neuro-oncology capacity in terms of workforce and available services in SSA. This is an ongoing online survey among a cross section of neuro-oncology practitioners spread across SSA countries to capture information on the distribution, number of available neuro-oncology care practitioners, capacity for neuropathology and molecular diagnosis, management of brain tumors, cancer registration, and tumor biobanking. The survey was disseminated by the Society for Neuro-oncology in SSA (SNOSSA). There were 83 respondents representing 15 countries and 52 health institutions: 46 tertiary, 4 secondary, 1 private and 1 other. Here, we present data on the 52 institutions. The prevalence of specialties was 87% neurosurgery, 75% anatomic pathology, 69% medical oncology, 64% neurology, 60% radiation oncology, and 39% neuropathology. For radiologic evaluation, 81% of institutions were reported to have both CT and MRI, 17% CT only, and one institution neither. For molecular testing, 46% have access to IHC or NGS testing, whereas 52% were reported to have neither. A neuro-oncology tumor board was reported at 58% of institutions. A general cancer registry is available in 64% of institutions, 31% have a brain tumor specific registry and 10% have a brain tumor biorepository. This study shows that SSA has substantial potential in neuro-oncology care practice capacity and facilities. Most significant gaps remain in areas such as neuropathology and molecular testing, which makes widespread implementation of the WHO 2021 diagnosis challenging. Understanding the prevalence of CNS tumor subtypes is also difficult due to low number of brain tumor registries and biobanks in SSA. The present findings reveal strategic opportunities, especially in neuropathology, tumor registries, biobanks, and infrastructure for IHC and NGS in SSA.
OTHR-05 FEASIBILITY STUDY ON BRAIN TUMOR BIOBANKING AND REGISTRY IN SUB-SAHARAN AFRICAN COUNTRIES: A QUESTIONNAIRE-BASED SURVEY
Eckel‐Passow, Jeanette E. , Ghomsi, Nathalie , Jenkins, Robert B. , Cheserem, Beverly , Odukoya, Lateef A , Kamson, David , Schroeder, Kristin , Fonkem, Ekokobe , Zerd, Francis

Mayo Clinic

Neuro-Oncology Advances | October 2, 2024 | Volume: 6 | Issue: Supplement_2 | Pages: ii5-ii5

10.1093/noajnl/vdae147.019 Get It

Abstract INTRODUCTION Brain tumors constitute significant morbidity and mortality in sub-Saharan Africa (SSA). Improvements in neuro-oncology practice and research have seen increased diagnosis of brain tumors. However, to our knowledge, there have been no previous projects on brain tumor genetics in SSA. To understand the feasibility of developing brain tumor biobanking and registries, this project aims to start by mapping out the current neuro-oncology capacity in terms of workforce and available services. METHODOLOGY We will conduct a descriptive questionnaire-based online survey among a cross section of neuro-oncology practitioners spread across SSA countries. The dissemination of the survey questionnaire will be facilitated by the Society for Neuro-oncology in SSA (SNOSSA). The Google designed questionnaire will capture information on the distribution, and number of available neuro-oncology care practitioners, capacity for brain tumor diagnosis and management, cancer registration, tumor biobanking, and research. CLINICAL IMPACT AND CONCLUSION This study will generate robust data from SSA, which can be used to improve future research and promote advocacy towards brain tumor diagnosis and management. This work will also serve as a pilot study for subsequent research that will focus on the development of brain tumor-specific registries and biorepositories in SSA.
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Buras, Matthew R., Carter, Rickey E. , Joyner, Michael J. , Bloch, Evan M. , Henderson, Jeffrey P. , Senefeld, Jonathon W. , Wright, R. Scott , Carter, Rickey E , Joyner, Michael J , Henderson, Jeffrey P , Shoham, Shmuel , Sullivan, David J , Casadevall, Arturo , Senefeld, Jonathon W , Dragotakes, Quigly , Johnson, Patrick W. , Gebo, Kelly A , Hanley, Daniel F. , Pirofski, Liise‐anne , Shoham, Shmuel , Tobian, Aaron A.R. , Wiggins, Chad C. , Paneth, Nigel , Sullivan, David , Casadevall, Arturo

Mayo Clinic

Proceedings of the National Academy of Sciences | October 1, 2024 | Volume: 121 | Issue: 41 | Pages: No page available

10.1073/pnas.2414957121 | PMID 39352932 Get It

In the Spring of 2020, the United States of America (USA) deployed COVID-19 convalescent plasma (CCP) to treat hospitalized patients. Over 500,000 patients were treated with CCP during the first year of the pandemic. In this study, we estimated the number of actual inpatient lives saved by CCP treatment in the United States of America based on CCP weekly use, weekly national mortality data, and CCP mortality reduction data from meta-analyses of randomized controlled trials and real-world data. We also estimate the potential number of lives saved if CCP had been deployed for 100% of hospitalized patients or used in 15 to 75% of outpatients. Depending on the assumptions modeled in stratified analyses, we estimated that CCP saved between 16,476 and 66,296 lives. The CCP ideal use might have saved as many as 234,869 lives and prevented 1,136,133 hospitalizations. CCP deployment was a successful strategy for ameliorating the impact of the COVID-19 pandemic in the USA. This experience has important implications for convalescent plasma use in future infectious disease emergencies.
Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk
Ni, Zhanmo , Kundu, Prosenjit , McKean, David , Wheeler, William , Albanes, Demetrius , Andreotti, Gabriella , Antwi, Samuel O. , Arslan, Alan A. , Bamlet, William R. , Freeman, Laura E. Beane , Berndt, Sonja I. , Bracci, Paige M. , Brennan, Paul , Buring, Julie E. , Gallinger, Steven , Gaziano, J. Michael , Giovannucci, Edward L. , Goodman, Phyllis J. , Haiman, Christopher A. , Hassan, Manal M. , Holly, Elizabeth A. , Li, Donghui , Oberg, Ann L. , Patel, Alpa V. , Peters, Ulrike , Visvanathan, Kala , White, Emily , Wolpin, Brian M. , Zhong, Jun, McKean, David F , Beane Freeman, Laura E , Chanock, Stephen Jacob , Gallinger, Steven , Gaziano, J Michael , Giles, Graham G , Giovannucci, Edward L , Goggins, Michael G , Goodman, Phyllis J , Haiman, Christopher A , Hassan, Manal M , Holly, Elizabeth A , Hung, Rayjean J , Katzke, Verena , Kooperberg, Charles , Kraft, Peter , Marchand, Loïc Le , Li, Donghui , McCullough, Marjorie L , Milne, Roger L , Moore, Steven C , Neale, Rachel E , Oberg, Ann L , Patel, Alpa V , Peters, Ulrike , Chaffee, Kari G. , Risch, Harvey A , Shu, Xiao-Ou , Smith-Byrne, Karl , Visvanathan, Kala , Wactawski-Wende, Jean , White, Emily , Wolpin, Brian M , Yu, Herbert , Zeleniuch-Jacquotte, Anne , Zheng, Wei , Zhong, Jun , Amundadottir, Laufey , Stolzenberg-Solomon, Rachael , Klein, Alison P , Antwi, Samuel O , Arslan, Alan A , Bamlet, William R , Albanes, Demetrius , Giles, Graham G. , Goggins, Michael , Hung, Rayjean J. , Kooperberg, Charles , Kraft, Peter , Marchand, Loı̈c Le , McCullough, Marjorie L. , Milne, Roger L. , Moore, Steven C. , Neale, Rachel Ε. , Rabe, Kari G. , Risch, Harvey A. , Shu, Xiao‐Ou , Wactawski‐Wende, Jean , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Zheng, Wei , Ámundadóttir, Laufey T. , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 13, 2024 | Volume: 33 | Issue: 9 | Pages: 1229-1239

10.1158/1055-9965.epi-24-0096 | PMID 38869494 Get It

Abstract Background: Pancreatic cancer is a leading cause of cancer-related death globally. Risk factors for pancreatic cancer include common genetic variants and potentially heavy alcohol consumption. We assessed if genetic variants modify the association between heavy alcohol consumption and pancreatic cancer risk. Methods: We conducted a genome-wide interaction analysis of single-nucleotide polymorphisms (SNP) by heavy alcohol consumption (more than three drinks per day) for pancreatic cancer in European ancestry populations from genome-wide association studies. Our analysis included 3,707 cases and 4,167 controls from case–control studies and 1,098 cases and 1,162 controls from cohort studies. Fixed-effect meta-analyses were conducted. Results: A potential novel region of association on 10p11.22, lead SNP rs7898449 (interaction P value (Pinteraction) = 5.1 × 10−8 in the meta-analysis; Pinteraction = 2.1 × 10−9 in the case–control studies; Pinteraction = 0.91 in the cohort studies), was identified. An SNP correlated with this lead SNP is an expression quantitative trait locus for the neuropilin 1 gene. Of the 17 genomic regions with genome-wide significant evidence of association with pancreatic cancer in prior studies, we observed suggestive evidence that heavy alcohol consumption modified the association for one SNP near LINC00673, rs11655237 on 17q25.1 (Pinteraction = 0.004). Conclusions: We identified a novel genomic region that may be associated with pancreatic cancer risk in conjunction with heavy alcohol consumption located near an expression quantitative trait locus for neuropilin 1, a protein that plays an important role in the development and progression of pancreatic cancer. Impact: This work can provide insights into the etiology of pancreatic cancer, particularly in heavy drinkers.
Non–Small Cell Lung Cancer, Version 4.2024
Riely, Gregory J. , Wood, Douglas E. , Ettinger, David S. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , DeCamp, Malcolm M., Desai, Aakash , Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Mullikin, Trey C. , Ng, Thomas, Owen, Dawn , Patel, Sandip Pravin , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hang, Lisa, Desai, Aakash P , Bharat, Ankit , Chang, Joe Y. , Chirieac, Lucian R. , Grotz, Travis E. , Juloori, Aditya , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Owen, Dwight H , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 16, 2024 | Volume: 22 | Issue: 4 | Pages: 249-274

10.6004/jnccn.2204.0023 | PMID 38754467 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for the treatment of patients with NSCLC, including diagnosis, primary disease management, surveillance for relapse, and subsequent treatment. The panel has updated the list of recommended targeted therapies based on recent FDA approvals and clinical data. This selection from the NCCN Guidelines for NSCLC focuses on treatment recommendations for advanced or metastatic NSCLC with actionable molecular biomarkers.
Therapeutic potential and impact of nanoengineered patient‐derived mesenchymal stem cells in a murine resection and recurrence model of human glioblastoma
Al‐kharboosh, Rawan , Bechtle, Alex, Zheng, Jiaying , Mondal, Sujan Kumar , Wilson, David R. , Perez‐Vega, Carlos , Green, Jordan J. , Quiñones‐Hinojosa, Alfredo , Perez-Vega, Carlos, Green, Jordan J , Zheng, Jiaying , Bechtle, Alexandra , Tzeng, Stephany Y.

Mayo Clinic

Bioengineering & Translational Medicine | May 8, 2024 | Volume: 9 | Issue: 6 | Pages: No page available

10.1002/btm2.10675 | PMID 39545093 Get It

Abstract Confounding results of engineered mesenchymal stem cells (MSCs) used as cellular vehicles has plagued technologies whereby success or failure of novel approaches may be dismissed or inaccurately ascribed solely to the biotechnology platform rather than suitability of the human donor. Polymeric materials were screened for non‐viral engineering of MSCs from multiple human donors to deliver bone morphogenic protein‐4 (BMP4), a protein previously investigated in clinical trials for glioblastoma (GBM) to combat a subpopulation of highly invasive and tumorigenic clones. A “smart technology” that target the migratory and stem‐like nature of GBM will require: (1) a cellular vehicle (MSC) which can scavenge and target residual cells left behind after surgical debulking and deliver; (2) anti‐glioma cargo (BMP4). Multiple MSC donors are safely engineered, though varied in susceptibility to accept BMP4 due to intrinsic characteristics revealed by their molecular signatures. Efficiency is compared via secretion, downstream signaling, differentiation, and anti‐proliferative properties across all donors. In a clinically relevant resection and recurrence model of patient‐derived human GBM, we demonstrate that nanoengineered MSCs are not “donor agnostic” and efficacy is influenced by the inherent suitability of the MSC to the cargo. Therefore, donor profiles hold greater influence in determining downstream outcomes than the technical capabilities of the engineering technology.
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial
Park, Han-Sol , Yin, Anna , Barranta, Caelan, Caputo, Christopher , Sachithanandham, Jaiprasath , Li, Maggie , Yoon, Steve, Sitaras, Ioannis , Jedlicka, Anne , Eby, Yolanda , Ram, Malathi , Fernández, Reinaldo E. , Baker, Owen R. , Fukuta, Yuriko , Patel, Bela , Heath, Sonya L. , Spivak, Emily S , Huamán, Moisés A. , Blair, Janis E. , Gerber, Jonathan M. , Petrini, Joann, Broderick, Patrick , Rausch, William, Cordisco, Marie Elena , Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie , Cruser, Daniel, Oei, Kevin , Abinante, Matthew, Hammitt, Laura L. , Forthal, Donald N. , Cachay, Edward R. , Marshall, Christi E., Lane, Karen , McBee, Nichol , Gawad, Amy L., Karlen, Nicky, Singh, Atika, Jabs, Douglas A. , Shade, David , Lau, Bryan , Ehrhardt, Stephan , Baksh, Sheriza , Ou, Jiangda , Na, Yu Bin , Knoll, Maria Deloria , Ornelas-Gatdula, Elysse, Gniadek, Thomas J. , Wu, Jinke, Ndahiro, Nelson , Betenbaugh, Michael J. , Ziman, Alyssa , Bloch, Evan M. , Laeyendecker, Oliver , Ziman, Alyssa , Huaman, Moises A , Laeyendecker, Oliver , Lee, John S. , Shenoy, Aarthi , Mosnaim, Giselle S , Levine, Adam C , Meisenberg, Barry R. , Anjan, Shweta , Currier, Judith S. , Paxton, James H , Sutcliffe, Catherine G , Zand, Martin S. , Raval, Jay S. , Kassaye, Seble , Yarava, Anusha , Ford, Daniel E , Appel, Lawrence J. , Shapiro, Janna R. , Arroyo‐Currás, Netzahualcóyotl , Caturegli, Patrizio , Hanley, Daniel F. , Casadevall, Arturo , Shoham, Shmuel , Gebo, Kelly A , Tobian, Aaron A.R. , Pekosz, Andrew , Klein, Sabra L , Sullivan, David

Mayo Clinic

JCI Insight | April 23, 2024 | Volume: 9 | Issue: 8 | Pages: No page available

10.1172/jci.insight.178460 | PMID 38483534 Get It

BACKGROUND COVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined. METHODS This secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization–equivalent anti–Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis. RESULTS SARS-CoV-2 anti–S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01). CONCLUSION In unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors’ antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use. TRIAL REGISTRATION ClinicalTrials.gov NCT04373460. FUNDING Department of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation.
Passive immunotherapies for the next influenza pandemic
Focosi, Daniele , Senefeld, Jonathon W. , Joyner, Michael J. , Sullivan, David , Senefeld, Jonathon W , Sullivan, David J , Joyner, Michael J , Focosi, Daniele , Franchini, Massimo , Pekosz, Andrew , Maggi, Fabrizio , Casadevall, Arturo

Mayo Clinic

Reviews in Medical Virology | April 18, 2024 | Volume: 34 | Issue: 3 | Pages: No page available

10.1002/rmv.2533 | PMID 38635404 Get It

AbstractInfluenzavirus is among the most relevant candidates for a next pandemic. We review here the phylogeny of former influenza pandemics, and discuss candidate lineages. After briefly reviewing the other existing antiviral options, we discuss in detail the evidences supporting the efficacy of passive immunotherapies against influenzavirus, with a focus on convalescent plasma.